From the FDA Drug Label
2.1 Dosage The recommended starting dosage of MOUNJARO is 2.5 mg injected subcutaneously once weekly. Follow the dosage escalation below to reduce the risk of gastrointestinal adverse reactions The 2.5 mg dosage is for treatment initiation and is not intended for glycemic control. After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly. If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose. The maximum dosage of MOUNJARO is 15 mg injected subcutaneously once weekly.
The dosing regimen for Mounjaro (tirzepatide) in the treatment of Type 2 Diabetes Mellitus (Type 2 DM) is as follows:
- Starting dose: 2.5 mg injected subcutaneously once weekly
- Dosage escalation:
- Increase to 5 mg after 4 weeks
- Further increases in 2.5 mg increments after at least 4 weeks on the current dose
- Maximum dose: 15 mg injected subcutaneously once weekly 1
From the Research
Dosing Regimen for Mounjaro (Tirzepatide)
The dosing regimen for Mounjaro (tirzepatide) in the treatment of Type 2 Diabetes Mellitus (Type 2 DM) is as follows:
- Tirzepatide is administered via once-weekly subcutaneous injection 2, 3, 4, 5
- The recommended doses are 5 mg, 10 mg, and 15 mg per week 3, 4, 5
- Tirzepatide can be used as monotherapy or in combination with other oral glucose-lowering medications and insulin 2, 3, 4
Administration and Formulation
- Tirzepatide comes in single-dose prefilled pens and single-dose vials 2
- It is administered subcutaneously, once a week 2, 3, 4, 5
Clinical Trials and Efficacy
- The SURPASS clinical trials have demonstrated the efficacy and safety of tirzepatide in improving glycemic control and reducing body weight in adults with Type 2 DM 2, 6, 3, 4, 5
- Tirzepatide has been shown to be superior to other GLP-1 receptor agonists, such as semaglutide, in terms of glycemic control and weight loss 3, 4, 5